[e-drug] WHO'S Massive Effort Not Aggressive Enough

E-drug: WHO'S Massive Effort Not Aggressive Enough
---------------------------------------------
Author: Daniel BERMAN at MSF-GENEVA

     MSF Press Release:

     WHO'S "MASSIVE EFFORT" IS NOT AGGRESSIVE ENOUGH SAYS
     M�DECINS SANS FRONTI�RES

     Geneva, 4 October 2000 - -WHO's new "Massive Effort" to address
     HIV/Aids, tuberculosis and malaria is based on a faulty premise,
     according to comments made today by M�decins sans Fronti�res at the
     United Nations Geneva headquarters. MSF disagreed with WHO's claim
     that "each death [from these three diseases] can be avoided with low
     cost technologies that are available today." The "Massive Effort"
     advocacy campaign is being discussed this week with more than 80 NGOs
     in Winterthur, Switzerland. It is a response to the G8's new global
     battle against infectious diseases, announced at Okinawa last July.

     "Although we appreciate that WHO is raising awareness about the
     dramatic impact of communicable diseases in developing countries and
     the need for prevention, we believe that the current emphasis on
     'existing interventions' misleads the public into thinking that we
     already have the answers," said James Orbinski, President of MSF's
     International Council. "In fact, many effective medicines are either
     too expensive or don't exist. We think WHO's emerging plan fails to
     challenge the status quo."

     MSF strongly supports many of WHO's proposed solutions, such as bed
     nets for malaria prevention and additional funding for the current TB
     strategy (DOTS), but called on WHO to be more ambitious in the short
     and middle-term. WHO's approach to Aids was cited as an illustration
     of the problem.

     In its analysis to battle Aids, WHO outlines a series of prevention
     strategies and mentions the need to treat opportunistic infections.
     However, the drug cocktails (antiretrovirals) that have caused Aids
     deaths to plummet in wealthy countries are described as too expensive
     to consider for developing countries. In light of the fact that
     triple drug therapy can now be purchased for USD 800, MSF spoke of a
     moral obligation to begin treating patients where possible. Right now,
     some countries, such as Uganda, Ivory Coast and El Salvador are
     committed to expanding their Aids programs. MSF insists that these
     countries should receive assistance from WHO to secure affordable
     quality drugs.

     "We also need WHO to emphasize the fact that research and development
     is at a standstill for the diseases that most affect people in poor
     countries. We think that this message should be a critical part of
     the Massive Effort advocacy campaign being launched this week in
     Winterthur," said Orbinski. "Some of the public/private partnerships
     to find new drugs for TB and malaria may eventually yield results but
     the current level of activity needs to be dramatically increased. It
     is WHO that should be challenging national governments to ramp up
     public sector research for diseases that have been abandoned by the
     multinational drug industry."

     Of the 1,223 new drugs brought to market between 1975 and 1997, only
     13 are indicated to treat tropical diseases. In a time when the
     private sector has shifted resources to more lucrative lifestyle
     diseases such as baldness and obesity, governments must fill this
     void.

     Communicable diseases are responsible for 60 percent of the total
     disease burden in developing countries and kill 5.5 million people
     each year. World-wide 34 million people are infected with HIV, one
     person dies every 30 seconds from malaria and nearly one billion
     people will be newly infected with TB over the next twenty years.

     For further information please call Daniel Berman at +41 79 286 9649

     Daniel Berman
     Access to Essential Medicines Campaign
     MSF
     daniel_berman@geneva.msf.org

--
Send mail for the `E-Drug' conference to `e-drug@usa.healthnet.org'.
Mail administrative requests to `majordomo@usa.healthnet.org'.
For additional assistance, send mail to: `owner-e-drug@usa.healthnet.org'.